Artal Group’s Celldex Therapeutics CLDX Stock Holding History

Artal Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-253,000	Closed	-$10.6M	–	119
2024 Q1	$10.6M	Buy	+253,000	New	+$10.4M	0.27%	43
2021 Q1	–	Sell	-400,000	Closed	-$7.01M	–	155
2020 Q4	$7.01M	Buy	+400,000	New	+$7.2M	0.15%	99
2018 Q1	–	Sell	-23,356	Closed	-$995K	–	118
2017 Q4	$995K	Sell	23,356 -21,644	-48%	-$927K	0.02%	114
2017 Q3	$1.93M	Hold	45,000	–	–	0.03%	94
2017 Q2	$1.67M	Hold	45,000	–	–	0.03%	98
2017 Q1	$2.44M	Hold	45,000	–	–	0.05%	80
2016 Q4	$2.39M	Hold	45,000	–	–	0.05%	74
2016 Q3	$2.73M	Hold	45,000	–	–	0.05%	79
2016 Q2	$2.96M	Hold	45,000	–	–	0.06%	54
2016 Q1	$2.55M	Buy	45,000 +20,000	+80%	+$2.25M	0.05%	49
2015 Q4	$5.88M	Hold	25,000	–	–	0.11%	62
2015 Q3	$3.95M	Buy	25,000 +8,333	+50%	+$2.36M	0.09%	61
2015 Q2	$6.3M	Buy	+16,667	New	+$6.62M	0.27%	53

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's CLDX Position: Q2 2024 in Review

Artal Group sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 253,000 shares — an estimated $10.6M sold.

Artal Group first reported a position in CLDX in Q2 2015 and held it in 13 quarters. The position peaked at $10.6M in Q1 2024. 182 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

Artal Group reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
Artal Group sold 253,000 Celldex Therapeutics shares in Q2 2024, an estimated $10.6M.
Artal Group first reported a position in Celldex Therapeutics in Q2 2015 and held it in 13 quarters.
Artal Group's Celldex Therapeutics position peaked at $10.6M in Q1 2024.
182 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.